Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto: Reductase (AKR) 1C3

Toxicology Letters

Volumn 181, Issue 1, 2008, Pages 1-6

  Novotna, Romana ^a   Wsol, Vladimir ^a   Xiong, Guangming ^b   Maser, Edmund ^b  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Aldo keto reductases (AKR); Carbonyl reduction; Chemotherapeutics; Doxorubicin; Drug metabolism; Oraci

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; 3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; AKR1C3 PROTEIN, HUMAN; ANTINEOPLASTIC ANTIBIOTIC; DOXORUBICIN; ETHANOLAMINE DERIVATIVE; ISOQUINOLINE DERIVATIVE; ORACINE; RECOMBINANT PROTEIN;

ARTICLE; BIOSYNTHESIS; GENETICS; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; PHYSIOLOGY;

3-HYDROXYSTEROID DEHYDROGENASES; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; ETHANOLAMINES; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; ISOQUINOLINES; RECOMBINANT PROTEINS;

EID: 56149115318     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2008.06.858     Document Type: Article

References (37)

1. Andersson, S., Moghrabi, N., 1997. Physiology and molecular genetics of 17 betahydroxysteroid dehydrogenases. Steroids 62, 143-147.
2. Ax,W., Soldan, M., Koch, L., Maser, E., 2000. Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. Biochem. Pharmacol. 59, 293-300.
3. Byrns, M.C., Steckelbroeck, S., Penning, T.M., 2008. An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies. Biochem. Pharmacol. 75, 484-493.
4. Degtiar,W.G., Kushlinsky, N.E., 2001. 3Alpha-hydroxysteroid dehydrogenase in animal and human tissues. Biochemistry (Mosc.) 66, 256-266.
5. Dufort, I., Soucy, P., Labrie, F., Luu-The, V., 1996. Molecular cloning of human type 3 3 alpha-hydroxysteroid dehydrogenase that differs from 20 alpha-hydroxysteroid dehydrogenase by seven amino acids. Biochem. Biophys. Res. Commun. 228, 474-479.
6. Dufort, I., Rheault, P., Huang, X.F., Soucy, P., Luu-The, V., 1999. Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase. Endocrinology 140, 568-574.
7. Dufort, I., Labrie, F., Luu-The, V., 2001. Human types 1 and 3 3 alpha-hydroxysteroid dehydrogenases: differential lability and tissue distribution. J. Clin. Endocrinol. Metab. 86, 841-846.
8. Fogli, S., Danesi, R., Innocenti, F., Di, P.A., Bocci, G., Barbara, C., Del, T.M., 1999. An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma. Ther. Drug Monit. 21, 367-375.
9. Fung, K.M., et al., 2006. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocrinol. Relat. Cancer 13, 169-180.
10. Hoffmann, F., Maser, E., 2007. Carbonyl reductases and pluripotent hydroxysteroid dehydrogenases of the short-chain dehydrogenase/reductase superfamily. Drug Metab. Rev. 39, 87-144.
11. Jez, J.M., Bennett, M.J., Schlegel, B.P., Lewis, M., Penning, T.M., 1997. Comparative anatomy of the aldo-keto reductase superfamily. Biochem. J. 326 (Pt 3), 625-636.
12. Ji, Q., Aoyama, C., Nien, Y.D., Liu, P.I., Chen, P.K., Chang, L., Stanczyk, F.Z., Stolz, A., 2004. Selective loss of AKR1C1 and AKR1C2 in breast cancer and their potential effect on progesterone signaling. Cancer Res. 64, 7610-7617.
13. Jörnvall, H., Persson, B., Krook, M., Atrian, S., Gonzalez-Duarte, R., Jeffery, J., Ghosh, D., 1995. Short-chain dehydrogenases/reductases (SDR). Biochemistry 34, 6003-6013.
14. Khanna, M., Qin, K.N., Wang, R.W., Cheng, K.C., 1995. Substrate specificity, gene structure, and tissue-specific distribution of multiple human 3α-hydroxysteroid dehydrogenases. J. Biol. Chem. 270, 20162-20168.
15. Labrie, F., Luu-The, V., Lin, S.X., Simard, J., Labrie, C., El-Alfy,M., Pelletier, G., Belanger, A., 2000. Intracrinology: role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and disease. J. Mol. Endocrinol. 25, 1-16.
16. Lin, H.K., Jez, J.M., Schlegel, B.P., Peehl, D.M., Pachter, J.A., Penning, T.M., 1997. Expression and characterization of recombinant type 2 3 alpha-hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3 alpha/17 beta-HSD activity and cellular distribution. Mol. Endocrinol. 11, 1971-1984.
17. Lin, H.K., Steckelbroeck, S., Fung, K.M., Jones, A.N., Penning, T.M., 2004. Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate. Steroids 69, 795-801.
18. Lukacik, P., Kavanagh, K.L., Oppermann, U., 2006. Structure and function of human 17beta-hydroxysteroid dehydrogenases. Mol. Cell Endocrinol. 248, 61-71.
19. Maser, E., 1995. Xenobiotic carbonyl reduction and physiological steroid oxidoreduction-the pluripotency of several hydroxysteroid dehydrogenases. Biochem. Pharmacol. 49, 421-440.
20. Matsuura, K., Shiraishi, H., Hara, A., Sato, K., Deyashiki, Y., Ninomiya, M., Sakai, S., 1998. Identification of a principal mRNA species for human 3alpha-hydroxysteroid dehydrogenase isoform (AKR1C3) that exhibits high prostaglandin D2 11-ketoreductase activity. J. Biochem. (Tokyo) 124, 940- 946.
21. Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., Gianni, L., 2004. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56, 185-229.
22. Olson, R.D., Mushlin, P.S., Brenner, D.E., Fleischer, S., Cusack, B.J., Chang, B.K., Boucek Jr., R.J., 1988. Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc. Natl. Acad. Sci. U.S.A. 85, 3585-3589.
23. Oppermann, U.C., Maser, E., 2000. Molecular and structural aspects of xenobiotic carbonyl metabolizing enzymes. Role of reductases and dehydrogenases in xenobiotic phase I reactions. Toxicology 144, 71-81.
24. Penning, T.M., Pawlowski, J.E., Schlegel, B.P., Jez, J.M., Lin, H.K., Hoog, S.S., Bennett, M.J., Lewis, M., 1996. Mammalian 3α-hydroxysteroid dehydrogenases. Steroids 61, 508-523.
25. Penning, T.M., Burczynski, M.E., Jez, J.M., Hung, C.F., Lin, H.K., Ma, H., Moore, M., Palackal, N., Ratnam, K., 2000. Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem. J. 351, 67-77.
26. Penning, T.M., Burczynski, M.E., Jez, J.M., Lin, H.K., Ma, H., Moore, M., Ratnam, K., Palackal, N., 2001. Structure-function aspects and inhibitor design of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3). Mol. Cell Endocrinol. 171, 137-149.
27. Penning, T.M., Steckelbroeck, S., Bauman, D.R., Miller,M.W., Jin, Y., Peehl, D.M., Fung, K.M., Lin, H.K., 2006. Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors. Mol. Cell Endocrinol. 248, 182-191.
28. Plebuch, M., Soldan, M., Hungerer, C., Koch, L., Maser, E., 2007. Increased resistance of tumor cells to daunorubicin after transfection of cDNAs coding for anthracycline inactivating enzymes. Cancer Lett. 255, 49-56.
29. Qin, K.N.,New, M.I., Cheng, K.C., 1993. Molecular cloning of multiple cDNAs encoding human enzymes structurally related to 3 alpha-hydroxysteroid dehydrogenase. J. Steroid Biochem. Mol. Biol. 46, 673-679.
30. Seckl, J.R., Walker, B.R., 2001. Minireview: 11beta-hydroxysteroid dehydrogenase type 1-a tissue-specific amplifier of glucocorticoid action. Endocrinology 142, 1371-1376.
31. Simpson, E.R., Clyne, C., Speed, C., Rubin, G., Bulun, S., 2001. Tissue-specific estrogen biosynthesis and metabolism. Ann. NY Acad. Sci. 949, 58-67.
32. Stanbrough, M., Bubley, G.J., Ross, K., Golub, T.R., Rubin, M.A., Penning, T.M., Febbo, P.G., Balk, S.P., 2006. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 66, 2815-2825.
33. Vihko, P., et al., 2005. Enzymes as modulators in malignant transformation. J. Steroid Biochem. Mol. Biol. 93, 277-283.
34. Vihko, P., Herrala, A., Harkonen, P., Isomaa, V., Kaija, H., Kurkela, R., Pulkka, A., 2006. Control of cell proliferation by steroids: the role of 17HSDs. Mol. Cell Endocrinol. 248, 141-148.
35. Wsol, V., Kvasnickova, E., Szotakova, B., Hais, I.M., 1996. High-performance liquid chromatographic assay for the separation and characterization of metabolites of the potential cytostatic drug oracine. J. Chromatogr. B Biomed. Appl. 681, 169-175.
36. Wsol, V., Szotakova, B., Skalova, L., Cepkova, H., Kvasnickova, E., 2000. The main metabolic pathway of oracin, a new potential cytostatic drug, in human liver microsomes and cytosol: stereoselectivity of reoxidation of the principal metabolite 11-dihydrooracin to oracin. Enantiomer 5, 263- 270.
37. Wsol, V., Szotakova, B., Martin, H.J., Maser, E., 2007. Aldo-keto reductases (AKR) from the AKR1C subfamily catalyze the carbonyl reduction of the novel anticancer drug oracin in man. Toxicology 238, 111-118.